Return to Disorders Listing

return to Main Menu

What is Alzheimer's Disease?
Alzheimer’s disease (AD) is a progressive, neurodegenerative disease characterized in the brain by abnormal clumps (amyloid plaques) and tangled bundles of fibers (neurofibrillary tangles) composed of misplaced proteins. Age is the most important risk factor for AD; the number of people with the disease doubles every 5 years beyond age 65. Three genes have been discovered that cause early onset (familial) AD. Other genetic mutations that cause excessive accumulation of amyloid protein are associated with age-related (sporadic) AD. Symptoms of AD include memory loss, language deterioration, impaired ability to mentally manipulate visual information, poor judgment, confusion, restlessness, and mood swings. Eventually AD destroys cognition, personality, and the ability to function. The early symptoms of AD, which include forgetfulness and loss of concentration, are often missed because they resemble natural signs of aging.

Is there any treatment?
There is no cure for AD and no way to slow the progression of the disease. For some people in the early or middle stages of AD, medication such as tacrine (Cognex) may alleviate some cognitive symptoms. Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl) may keep some symptoms from becoming worse for a limited time. Also, some medications may help control behavioral symptoms such as sleeplessness, agitation, wandering, anxiety, and depression.

What is the prognosis?
AD is a progressive disease, but its course can vary from 5 to 20 years. The most common cause of death in AD patients is infection.

What research is being done?
The NINDS conducts and supports research on neurodegenerative and dementing disorders, including AD. Scientists are currently studying or testing different types of drugs and other substances to determine if they can stop AD progression, including nonsteroidal anti-inflammatory drugs (NSAIDS), statins (such as those used for lowering cholesterol), folic acid, gingko biloba, and vitamins E, B6, and B12. Studies in basic science are also exploring the potential of vaccines. The National Institute on Aging and the National Institute of Mental Health also support research related to AD

 

 

Select this link to view a list of studies currently seeking patients.
 

 

 Organizations

 

Alzheimer's Disease Education and Referral Center (ADEAR)
P.O. Box 8250
Silver Spring, MD 20907-8250
adear@alzheimers.org
http://www.alzheimers.org
Tel: 301-495-3311 800-438-4380
Fax: 301-495-3334
 

 

Alzheimer's Association
919 North Michigan Avenue
Suite 1100
Chicago, IL 60611-1676
info@alz.org
http://www.alz.org
Tel: 312-335-8700 800-272-3900
Fax: 312-335-1110

 

 

John Douglas French Alzheimer's Foundation
11620 Wilshire Blvd.
Suite 270
Los Angeles, CA 90025
jdfaf@earthlink.net
http://www.jdfaf.org
Tel: 310-445-4650 800-477-2243
Fax: 310-479-0516

 

 

Family Caregiver Alliance
690 Market Street
Suite 600
San Francisco, CA 94104
info@caregiver.org
http://www.caregiver.org
Tel: 415-434-3388 800-445-8106
Fax: 415-434-3508

 

 

American Health Assistance Foundation
22512 Gateway Center Drive
Clarksburg, MD 20871
info@ahaf.org
http://www.ahaf.org
Tel: 301-948-3244 800-437-AHAF (2423)
Fax: 301-258-9454

 

 

C-Mac Informational Services/Caregiver News [For Alzheimer's Type Dementia Caregivers]
271 Cedar Lane
East Meadow, NY 11554-2720
caregiver_cmi@hotmail.com
http://www.caregivernews.org
Tel: 516-481-6682
Fax: 516-486-7820

Return to Disorders Listing

return to Main Menu